183 related articles for article (PubMed ID: 17324252)
1. Gene promoter hypermethylation in ductal lavage fluid from healthy BRCA gene mutation carriers and mutation-negative controls.
Locke I; Kote-Jarai Z; Fackler MJ; Bancroft E; Osin P; Nerurkar A; Izatt L; Pichert G; Gui GP; Eeles RA
Breast Cancer Res; 2007; 9(1):R20. PubMed ID: 17324252
[TBL] [Abstract][Full Text] [Related]
2. Gene methylation in breast ductal fluid from BRCA1 and BRCA2 mutation carriers.
Antill YC; Mitchell G; Johnson SA; Devereux L; Milner A; Di Iulio J; Lindeman GJ; Kirk J; Phillips KA; Campbell IG
Cancer Epidemiol Biomarkers Prev; 2010 Jan; 19(1):265-74. PubMed ID: 20056647
[TBL] [Abstract][Full Text] [Related]
3. BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers.
Vos S; Moelans CB; van Diest PJ
Breast Cancer Res; 2017 May; 19(1):64. PubMed ID: 28569220
[TBL] [Abstract][Full Text] [Related]
4. CpG island tumor suppressor promoter methylation in non-BRCA-associated early mammary carcinogenesis.
Vasilatos SN; Broadwater G; Barry WT; Baker JC; Lem S; Dietze EC; Bean GR; Bryson AD; Pilie PG; Goldenberg V; Skaar D; Paisie C; Torres-Hernandez A; Grant TL; Wilke LG; Ibarra-Drendall C; Ostrander JH; D'Amato NC; Zalles C; Jirtle R; Weaver VM; Seewaldt VL
Cancer Epidemiol Biomarkers Prev; 2009 Mar; 18(3):901-14. PubMed ID: 19258476
[TBL] [Abstract][Full Text] [Related]
5. Loss of heterozygosity at the BRCA1 and BRCA2 loci detected in ductal lavage fluid from BRCA gene mutation carriers and controls.
Locke I; Kote-Jarai Z; Bancroft E; Bullock S; Jugurnauth S; Osin P; Nerurkar A; Izatt L; Pichert G; Gui GP; Eeles RA
Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1399-402. PubMed ID: 16835343
[TBL] [Abstract][Full Text] [Related]
6. DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma.
Fackler MJ; McVeigh M; Evron E; Garrett E; Mehrotra J; Polyak K; Sukumar S; Argani P
Int J Cancer; 2003 Dec; 107(6):970-5. PubMed ID: 14601057
[TBL] [Abstract][Full Text] [Related]
7. Methylation not a frequent "second hit" in tumors with germline BRCA mutations.
Dworkin AM; Spearman AD; Tseng SY; Sweet K; Toland AE
Fam Cancer; 2009; 8(4):339-46. PubMed ID: 19340607
[TBL] [Abstract][Full Text] [Related]
8. BRCA2 carriers with male breast cancer show elevated tumour methylation.
Deb S; Gorringe KL; Pang JB; Byrne DJ; Takano EA; ; Dobrovic A; Fox SB
BMC Cancer; 2017 Sep; 17(1):641. PubMed ID: 28893223
[TBL] [Abstract][Full Text] [Related]
9. A systematic review on the frequency of BRCA promoter methylation in breast and ovarian carcinomas of BRCA germline mutation carriers: Mutually exclusive, or not?
Vos S; van Diest PJ; Moelans CB
Crit Rev Oncol Hematol; 2018 Jul; 127():29-41. PubMed ID: 29891109
[TBL] [Abstract][Full Text] [Related]
10. Promoter hypermethylation patterns in fallopian tube epithelium of BRCA1 and BRCA2 germ line mutation carriers.
Bijron JG; van der Groep P; van Dorst EB; Seeber LM; Sie-Go DM; Verheijen RH; van Diest PJ
Endocr Relat Cancer; 2012 Feb; 19(1):69-81. PubMed ID: 22143498
[TBL] [Abstract][Full Text] [Related]
11. Germline promoter hypermethylation in BRCA1 and BRCA2 genes is not present in hereditary breast cancer patients.
Rodríguez-Balada M; Roig B; Melé M; Salvat M; Martorell L; Borràs J; Gumà J
Clin Transl Oncol; 2018 Sep; 20(9):1226-1231. PubMed ID: 29404838
[TBL] [Abstract][Full Text] [Related]
12. Nipple aspiration and ductal lavage in women with a germline BRCA1 or BRCA2 mutation.
Mitchell G; Antill YC; Murray W; Kirk J; Salisbury E; Lindeman GJ; Di Iulio J; Milner AD; Devereaux L; Phillips KA
Breast Cancer Res; 2005; 7(6):R1122-31. PubMed ID: 16457692
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of promoter hypermethylation detection in serum as a diagnostic tool for breast carcinoma in Korean women.
Kim JH; Shin MH; Kweon SS; Park MH; Yoon JH; Lee JS; Choi C; Fackler MJ; Sukumar S
Gynecol Oncol; 2010 Aug; 118(2):176-81. PubMed ID: 20466412
[TBL] [Abstract][Full Text] [Related]
14. Detection of breast cancer in nipple aspirate fluid by CpG island hypermethylation.
Krassenstein R; Sauter E; Dulaimi E; Battagli C; Ehya H; Klein-Szanto A; Cairns P
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):28-32. PubMed ID: 14734448
[TBL] [Abstract][Full Text] [Related]
15. Promoter methylation patterns of ATM, ATR, BRCA1, BRCA2 and p53 as putative cancer risk modifiers in Jewish BRCA1/BRCA2 mutation carriers.
Kontorovich T; Cohen Y; Nir U; Friedman E
Breast Cancer Res Treat; 2009 Jul; 116(1):195-200. PubMed ID: 18642075
[TBL] [Abstract][Full Text] [Related]
16. Very high frequency of hypermethylated genes in breast cancer metastasis to the bone, brain, and lung.
Mehrotra J; Vali M; McVeigh M; Kominsky SL; Fackler MJ; Lahti-Domenici J; Polyak K; Sacchi N; Garrett-Mayer E; Argani P; Sukumar S
Clin Cancer Res; 2004 May; 10(9):3104-9. PubMed ID: 15131050
[TBL] [Abstract][Full Text] [Related]
17. Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer.
Potapova A; Hoffman AM; Godwin AK; Al-Saleem T; Cairns P
Cancer Res; 2008 Feb; 68(4):998-1002. PubMed ID: 18281473
[TBL] [Abstract][Full Text] [Related]
18. Quantitative assessment of DNA hypermethylation in the inflammatory and non-inflammatory breast cancer phenotypes.
Van der Auwera I; Bovie C; Svensson C; Limame R; Trinh XB; van Dam P; Van Laere SJ; Van Marck E; Vermeulen PB; Dirix LY
Cancer Biol Ther; 2009 Dec; 8(23):2252-9. PubMed ID: 19829046
[TBL] [Abstract][Full Text] [Related]
19. BRCA1 promoter methylation predicts adverse ovarian cancer prognosis.
Chiang JW; Karlan BY; Cass L; Baldwin RL
Gynecol Oncol; 2006 Jun; 101(3):403-10. PubMed ID: 16360812
[TBL] [Abstract][Full Text] [Related]
20. Atypia and DNA methylation in nipple duct lavage in relation to predicted breast cancer risk.
Euhus DM; Bu D; Ashfaq R; Xie XJ; Bian A; Leitch AM; Lewis CM
Cancer Epidemiol Biomarkers Prev; 2007 Sep; 16(9):1812-21. PubMed ID: 17855699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
